PACBHealthcare · Medical DevicesThe 8 Wall Street analysts covering Pacific Biosciences of California, Inc. hold a median 12-month price target of $3 — +15.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Pacific Biosciences of California, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (95): Sales and profits are climbing, and climbing faster than before.
Issuance (30): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PACB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +15.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | UBS | Assumes | Neutral | $1.50 → $1.35 |
| 11 May 2026 | Barclays | Maintains | Underweight | $1.00 → $1.50 |
| 11 May 2026 | Barclays | Maintains | Underweight | — |
| 14 Apr 2026 | Barclays | Maintains | Underweight | — |
| 6 Mar 2026 | Barclays | Downgrade | Underweight | — |
| 15 Dec 2025 | Barclays | Maintains | Equal-Weight | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 10 Nov 2025 | Stephens & Co. | Maintains | Overweight | — |
| 11 Aug 2025 | Piper Sandler | Maintains | Neutral | — |
| 25 June 2025 | Barclays | Maintains | Equal-Weight | — |
| 15 May 2025 | Piper Sandler | Maintains | Neutral | — |
| 15 May 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 10 Apr 2025 | Canaccord Genuity | Maintains | Buy | — |
| 25 Mar 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 20 Feb 2025 | Piper Sandler | Reiterates | Neutral | — |
| 18 Feb 2025 | Goldman Sachs | Maintains | Neutral | — |
| 18 Feb 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 14 Feb 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 23 Jan 2025 | Goldman Sachs | Maintains | Neutral | — |
| 11 Nov 2024 | Piper Sandler | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PACB appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Pacific Biosciences of California, Inc. returned +34.3% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 23% of US stocks
Cheaper than 98% of US stocks
Cheaper than 48% of US stocks
Higher than 24% of US stocks
Higher than 35% of US stocks
Higher than 37% of US stocks
Higher than 13% of US stocks
Higher than 7% of US stocks
Higher than 2% of US stocks
Higher than 23% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pacific Biosciences of California, Inc. has a market value of $811.3M and an enterprise value of $1.3B.
Revenue in the twelve months to 30 June 2026: $159.3M. The latest quarter shrank 1.9% year on year.
Net income over the same four quarters: −$131.4M, a −82.5% net margin.
Diluted earnings per share, trailing twelve months: $−0.43.
Free cash flow in the twelve months to 30 June 2026: −$130.5M.
Trailing P/E: −1.4×; forward P/E: −6.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Pacific Biosciences of California, Inc. employs 485 people — $328K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pacific Biosciences of California, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Pacific Biosciences of California (PACB) closed at $2.90 in the latest trading session, up 2.47% from the previous day. The headline notes that the gain came as the broader market dipped.
Why it matters — PACB watchers may note the stock’s session gain and how it moved relative to the market described in the item.
PacBio announced that its management will participate in upcoming investor conferences.
Why it matters — PACB watchers may note the planned opportunities for management to engage with investors.
Zacks Investment Research cites PacBio’s growing clinical adoption, advanced sequencing technologies, and rising consumables sales as growth supports, while noting funding headwinds and continued margin pressure.
Why it matters — These competing growth drivers and financial pressures are relevant to tracking PACB’s business outlook.
Pacific Biosciences of California (PACB) settled at $2.06 on the latest trading day, down 3.74% from its previous close.
Why it matters — The decline records PACB’s latest daily share-price movement for investors following the stock.
PacBio and Verily Health announced a multi-year strategic collaboration. The excerpt says Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows.
Why it matters — The collaboration links PacBio's HiFi sequencing with Verily's research data and analysis workflows for biomedical AI.
The 8 Wall Street analysts covering Pacific Biosciences of California, Inc. have a median 12-month price target of $3, with estimates ranging from $1.25 to $3.05. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Pacific Biosciences of California, Inc., 4 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Pacific Biosciences of California, Inc. 57 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Pacific Biosciences of California, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +15.2% from the last close, and Ticker Nerd's factor model ranks Pacific Biosciences of California, Inc. 57 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pacific Biosciences of California, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PACB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.25 to $3.05 over the next 12 months.
Pacific Biosciences of California, Inc. returned +34.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Pacific Biosciences of California, Inc. is a life sciences technology company that develops, manufactures, and markets advanced genetic sequencing solutions.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts". Pacific Biosciences of California (PACB) closed at $2.90 in the latest trading session, up 2.47% from the previous day. The headline notes that the gain came as the broader market dipped.
Pacific Biosciences of California, Inc. is a life sciences technology company that develops, manufactures, and markets advanced genetic sequencing solutions. Its core offering is HiFi long-read sequencing, supported by Single Molecule, Real-Time technology designed to produce highly accurate, detailed views of DNA. The company provides sequencing instruments, consumables, reagent kits, sample-preparation products, binding kits, and related laboratory solutions for genomic analysis workflows. Its technologies serve research institutions, clinical laboratories, pharmaceutical and biotechnology companies, agricultural organizations, and other customers working with complex genetic material. Applications include human genome and germline analysis, oncology research, infectious disease and microbiology studies, plant and animal sciences, population genomics, and other fields requiring comprehensive DNA characterization. Pacific Biosciences of California, Inc. occupies a specialized role in the genomics market by supporting long-read analysis, which can help researchers investigate genetic regions and structural variations that may be difficult to resolve with shorter sequencing methods.
CEO Mr. Mark Van Oene Ph.D. · 485 employees · United States · https://www.pacb.com
